Analysts Are Bullish on Top Healthcare Stocks: Boston Scientific (BSX), Urogen Pharma (URGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSXResearch Report), Urogen Pharma (URGNResearch Report) and Zai Lab (ZLABResearch Report) with bullish sentiments.

Boston Scientific (BSX)

In a report released yesterday, Anthony Petrone from Jefferies maintained a Buy rating on Boston Scientific, with a price target of $55.00. The company’s shares closed last Wednesday at $44.31, close to its 52-week high of $46.29.

According to TipRanks.com, Petrone is a 4-star analyst with an average return of 9.3% and a 56.9% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Tarsus Pharmaceuticals, and Edwards Lifesciences.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $59.85, implying a 37.8% upside from current levels. In a report issued on September 21, Morgan Stanley also reiterated a Buy rating on the stock with a $53.00 price target.

See today’s analyst top recommended stocks >>

Urogen Pharma (URGN)

Jefferies analyst Chris Howerton maintained a Buy rating on Urogen Pharma today and set a price target of $55.00. The company’s shares closed last Wednesday at $16.98.

According to TipRanks.com, Howerton ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.4% and a 31.3% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Apellis Pharmaceuticals, and POINT Biopharma Global.

Currently, the analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $40.50.

Zai Lab (ZLAB)

In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Zai Lab, with a price target of $225.00. The company’s shares closed last Wednesday at $118.33.

According to TipRanks.com, Yee is a 4-star analyst with an average return of 9.5% and a 47.4% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sigilon Therapeutics, and Denali Therapeutics.

Zai Lab has an analyst consensus of Strong Buy, with a price target consensus of $215.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.